Roche Holding AG (OTCMKTS:RHHBY) Short Interest Up 37.3% in December

Roche Holding AG (OTCMKTS:RHHBY) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 3,887,775 shares, an increase of 37.3% from the November 30th total of 2,832,462 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 4,645,231 shares, the days-to-cover ratio is presently 0.8 days. Based on an average trading volume of 4,645,231 shares, the days-to-cover ratio is presently 0.8 days. Approximately 0.1% of the shares of the stock are short sold.

Roche Price Performance

Shares of OTCMKTS RHHBY traded up $0.07 during mid-day trading on Tuesday, reaching $51.87. The company had a trading volume of 341,337 shares, compared to its average volume of 2,172,778. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. Roche has a twelve month low of $34.75 and a twelve month high of $53.00. The stock’s 50 day moving average is $46.85 and its 200-day moving average is $43.17.

Institutional Investors Weigh In On Roche

Several institutional investors have recently made changes to their positions in RHHBY. Curio Wealth LLC bought a new stake in Roche during the third quarter valued at about $25,000. Oakworth Capital Inc. bought a new position in shares of Roche in the third quarter worth about $57,000. First Horizon Advisors Inc. lifted its position in shares of Roche by 81.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock worth $75,000 after purchasing an additional 826 shares during the last quarter. Salomon & Ludwin LLC boosted its stake in Roche by 256.6% during the 3rd quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company’s stock valued at $129,000 after purchasing an additional 2,053 shares during the period. Finally, Douglass Winthrop Advisors LLC acquired a new stake in Roche in the 3rd quarter valued at approximately $201,000.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Zacks Research lowered Roche from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. Morgan Stanley reissued an “underweight” rating on shares of Roche in a research note on Tuesday, December 2nd. Hsbc Global Res raised shares of Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Jefferies Financial Group cut shares of Roche from a “hold” rating to a “moderate sell” rating in a report on Monday, October 27th. Finally, JPMorgan Chase & Co. upgraded shares of Roche from an “underweight” rating to a “neutral” rating in a report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Roche currently has an average rating of “Moderate Buy” and an average target price of $57.00.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.